225 related articles for article (PubMed ID: 35013085)
1. Impaired antibody response to COVID-19 vaccination in advanced HIV infection.
Hassold N; Brichler S; Ouedraogo E; Leclerc D; Carroue S; Gater Y; Alloui C; Carbonnelle E; Bouchaud O; Mechai F; Cordel H; Delagreverie H
AIDS; 2022 Mar; 36(4):F1-F5. PubMed ID: 35013085
[TBL] [Abstract][Full Text] [Related]
2. High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
Pourcher V; Belin L; Soulie C; Rosenzwajg M; Marot S; Lacombe K; Valin N; Pialoux G; Calin R; Palacios C; Malet I; Zafilaza K; Tubiana R; Valantin MA; Klatzmann D; Calvez V; Simon-Tillaux N; Marcelin AG
AIDS; 2022 Sep; 36(11):1545-1552. PubMed ID: 35730380
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination.
Jongkees MJ; Geers D; Hensley KS; Huisman W; GeurtsvanKessel CH; Bogers S; Gommers L; Papageorgiou G; Jochems SP; den Hollander JG; Schippers EF; Ammerlaan HSM; Bierman WFW; van der Valk M; Berrevoets MAH; Soetekouw R; Langebeek N; Bruns AHW; Leyten EMS; Sigaloff KCE; van Vonderen MGA; Delsing CE; Branger J; Katsikis PD; Mueller YM; de Vries RD; Rijnders BJA; Brinkman K; Rokx C; Roukens AHE
J Infect Dis; 2023 Mar; 227(5):651-662. PubMed ID: 36402141
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center.
Tau L; Turner D; Adler A; Marom R; Ahsanov S; Matus N; Levi I; Gerber G; Lev S; Ziv-Baran T; Hagin D; Freund T; Grupper A; Halperin T
Open Forum Infect Dis; 2022 Apr; 9(4):ofac089. PubMed ID: 35355894
[TBL] [Abstract][Full Text] [Related]
6. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; de la Concepción MLR; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV.
Griffin DWJ; Pai Mangalore R; Hoy JF; McMahon JH
AIDS; 2023 Jul; 37(9):1345-1360. PubMed ID: 37070539
[TBL] [Abstract][Full Text] [Related]
8. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
12. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
[TBL] [Abstract][Full Text] [Related]
13. Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.
Mauas R; Urueña A; Cecchini D; Strada ML; Arietti S; Cassetti I; Nogueira NF; Salazar AS; Rodriguez VJ; Jones DL; Alcaide ML
AIDS; 2023 May; 37(6):941-946. PubMed ID: 36728228
[TBL] [Abstract][Full Text] [Related]
14. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.
Chammartin F; Griessbach A; Kusejko K; Audigé A; Epp S; Stoeckle MP; Eichenberger AL; Amstutz A; Schoenenberger CM; Hasse B; Braun DL; Rauch A; Trkola A; Briel M; Bucher HC; Günthard HF; Speich B; Abela IA;
AIDS; 2024 Feb; 38(2):217-222. PubMed ID: 37830908
[TBL] [Abstract][Full Text] [Related]
15. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
Chammartin F; Kusejko K; Pasin C; Trkola A; Briel M; Amico P; Stoekle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Mueller NJ; Rauch A; Koller MT; Günthard HF; Bucher HC; Speich B; Abela IA;
AIDS; 2022 Aug; 36(10):1465-1468. PubMed ID: 35876706
[TBL] [Abstract][Full Text] [Related]
16. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
Vergori A; Cozzi-Lepri A; Tavelli A; Mazzotta V; Azzini AM; Gagliardini R; Mastrorosa I; Latini A; Pellicanò G; Taramasso L; Ceccherini-Silberstein F; Giannella M; Tacconelli E; Marchetti G; Monforte AD; Antinori A;
Int J Infect Dis; 2024 Jul; 144():107065. PubMed ID: 38643867
[TBL] [Abstract][Full Text] [Related]
18. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV.
González de Aledo M; Cañizares A; Vázquez-Rodríguez P; Castro Á; Moldes L; López S; Míguez E; Bou G; Mena Á
AIDS; 2022 Apr; 36(5):691-695. PubMed ID: 34999608
[TBL] [Abstract][Full Text] [Related]
20. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
